- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | New findings shed light on cause of Huntington's disease progression | ||
| Fr | FDA's device chief calls for more authority to address supply chain shortages impacting pediatric, neonatal patients | ||
| Fr | WuXi AppTec sells US medical device testing business to NAMSA | ||
| Fr | 'Own JP Morgan, don't let JP Morgan own you': Biopharma-and Jill Biden-show up for JPM25 | ||
| Fr | Lykos still plotting path to approval for rejected MDMA therapy after 'productive' FDA meeting | ||
| Fr | Notch begins 'significant' layoffs, blames tough environment for preclinical cell therapy biotechs | ||
| Do | Boehringer's phase 3 schizophrenia program misses primary goal | ||
| Do | Google Cloud 'can't wait to see what's next'as Servier extends AI drug R&D pact | ||
| Do | Avacta expands peptide-drug conjugate study after seeing 10% response rate | ||
| Mi | JPM25: GE HealthCare, UCSF launch research hub for cancer, neurodegenerative disease imaging | ||
| Mi | OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients | ||
| Mi | Neumora's dig into phase 3 depression data disappoints analysts | ||
| Mi | FDA elevates Philips cardiac telemetry recall over unflagged ECG alerts, following 2 deaths | ||
| Mi | Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial | ||
| Mi | JPM25, Day 3: GSK's liver disease plans, the Biotech CEO Sisterhood, and more | ||
| Mi | JPM25: GSK's CSO shares science strategy behind deal-making, plus plans to build off GLP-1s-but not for obesity | ||
| Di | Daiichi Sankyo gins up antibody research project with German research institute | ||
| Di | N-Power links up with Synapse to add oncologists to clinical research network | ||
| Di | JPM25: Dexcom predicts 2025 growth, with Stelo pushing portfolio updates | ||
| Di | Umoja secures $100M series C to bring more CAR-Ts into the clinic | ||
| Di | Sling's oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3 | ||
| Di | RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront | ||
| Di | JPM25, Day 2: Trump admin health picks 'like a box of chocolates' | ||
| 13.01. | JPM25: Roche has access to $10B in M&A firepower per year, pharma CEO says. Where will it spend the money? | ||
| 13.01. | JPM25: AbbVie pens $1B deal for Simcere's phase 1 T-cell engager |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
